#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	13648	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2118	640.7	0	.	n	.	0	C1450T	SNP	1450	1450	C	1677	1677	T	777	T	714	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	13648	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2118	640.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1411	1411	C	801	C,T	744,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24626	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3680	667.8	0	.	n	.	0	T695C	SNP	695	695	T	1091	1091	C	729	C,A	688,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24626	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3680	667.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2367	2367	C	827	C	762	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24626	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3680	667.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2441	2441	A	775	A	732	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24626	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3680	667.8	1	SNP	n	C2597T	0	.	.	2597	2597	C	2993	2993	C	749	C	703	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_L_00516	folP.WHO_L_00516	1	1	27	1734	folP	855	855	100.0	folP.l15.c4.ctg.1	1584	109.1	1	SNP	p	R229S	0	.	.	685	687	CGC	1083	1085	CGC	172;176;180	C;G;C	158;162;163	folP.WHO_L_00516:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4950	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3415	144.5	1	SNP	p	S91F	0	.	.	271	273	TCC	676	678	TCC	165;165;168	T;C;C	152;152;155	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4950	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3415	144.5	1	SNP	p	D95N	0	.	.	283	285	GAC	688	690	GAC	174;174;169	G;A;C	158;158;156	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4950	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3415	144.5	1	SNP	p	D95G	0	.	.	283	285	GAC	688	690	GAC	174;174;169	G;A;C	158;158;156	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	1504	mtrR	633	633	99.84	mtrR.l15.c30.ctg.1	1309	114.6	0	.	p	.	0	D79N	NONSYN	235	237	GAT	555	557	AAT	218;214;214	A;A;T	198;196;193	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	1504	mtrR	633	633	99.84	mtrR.l15.c30.ctg.1	1309	114.6	1	SNP	p	G45D	0	.	.	133	135	GGC	453	455	GGC	194;192;196	G;G;C	183;178;182	mtrR.WHO_U_01459:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	748	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c17.ctg.1	1135	65.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_L_00611c	parC.WHO_L_00611c	1	1	27	4580	parC	2304	2304	99.78	parC.l15.c4.ctg.1	2902	157.2	1	SNP	p	S87I	0	.	.	259	261	AGT	560	562	AGT	191;190;192	A;G;T	176;177;176	parC.WHO_L_00611c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_L_00611c	parC.WHO_L_00611c	1	1	27	4580	parC	2304	2304	99.78	parC.l15.c4.ctg.1	2902	157.2	1	SNP	p	S87W	0	.	.	259	261	AGT	560	562	AGT	191;190;192	A;G;T	176;177;176	parC.WHO_L_00611c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_L_00611c	parC.WHO_L_00611c	1	1	27	4580	parC	2304	2304	99.78	parC.l15.c4.ctg.1	2902	157.2	1	SNP	p	S87R	0	.	.	259	261	AGT	560	562	AGT	191;190;192	A;G;T	176;177;176	parC.WHO_L_00611c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	3854	parE	1986	1986	99.9	parE.l15.c4.ctg.1	2738	140.3	0	.	p	.	0	V89A	NONSYN	265	267	GTC	612	614	GCC	165;167;171	G;C;C	142;149;141	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	3854	parE	1986	1986	99.9	parE.l15.c4.ctg.1	2738	140.3	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1575	1577	GGC	169;171;169	G;G;C	165;165;159	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.15.001	penA.15.001	1	1	27	3558	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2472	143.6	1	SNP	p	A311V	0	.	.	931	933	GCA	1280	1282	GCA	191;193;190	G;C;A	175;176;175	penA.15.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	3558	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2472	143.6	1	SNP	p	I312M	0	.	.	934	936	ATC	1283	1285	ATC	192;191;198	A;T;C	179;178;184	penA.15.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	3558	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2472	143.6	1	SNP	p	V316P	0	.	.	946	948	GTG	1295	1297	GTG	208;210;211	G;T;G,A	189;190;192,1	penA.15.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	3558	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2472	143.6	1	SNP	p	V316T	0	.	.	946	948	GTG	1295	1297	GTG	208;210;211	G;T;G,A	189;190;192,1	penA.15.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	3558	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2472	143.6	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1796	1798	ACC	158;157;160	A;C;C	141;143;150	penA.15.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	3558	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2472	143.6	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1850	1852	GCG	146;147;145	G;C;G	122;120;121	penA.15.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	3558	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2472	143.6	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1850	1852	GCG	146;147;145	G;C;G	122;120;121	penA.15.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	3558	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2472	143.6	1	SNP	p	G542S	0	.	.	1624	1626	GGC	1973	1975	GGC	145;144;141	G;G;C	134;133;131	penA.15.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	3558	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2472	143.6	1	SNP	p	G545S	0	.	.	1633	1635	GGC	1982	1984	GGC	145;145;140	G,T;G;C	133,1;133;128	penA.15.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	3558	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2472	143.6	1	SNP	p	P551S	0	.	.	1651	1653	CCG	2000	2002	CCG	126;128;127	C,G;C,G;G	87,7;90,1;89	penA.15.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	5348	ponA	2397	2397	99.92	ponA.l6.c4.ctg.1	3090	172.6	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1582	1584	CTG	185;185;185	C;T;G	165;165;166	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1960	porA	1146	1146	99.83	porA.l15.c17.ctg.1	1597	121.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	451	451	C	147	C	132	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2652	porB1b	1041	1041	96.18	porB1b.l15.c4.ctg.1	1497	176.3	0	.	p	.	0	T89S	NONSYN	265	267	ACC	574	576	AGC	205;204;206	A;G;C	194;194;198	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2652	porB1b	1041	1041	96.18	porB1b.l15.c4.ctg.1	1497	176.3	0	.	p	.	0	.	MULTIPLE	358	359	AA	666	667	CG	219;219	C;G	206;203	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2652	porB1b	1041	1041	96.18	porB1b.l15.c4.ctg.1	1497	176.3	0	.	p	.	0	.	MULTIPLE	361	362	GA	669	671	CAG	220;220;221	C;A;G	203;206;208	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2652	porB1b	1041	1041	96.18	porB1b.l15.c4.ctg.1	1497	176.3	0	.	p	.	0	N122K	NONSYN	364	366	AAC	673	675	AAA	220;222;223	A;A;A	206;208;209	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2652	porB1b	1041	1041	96.18	porB1b.l15.c4.ctg.1	1497	176.3	0	.	p	.	0	F131Y	NONSYN	391	393	TTT	700	702	TAT	243;245;245	T;A;T	226;226;223	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2652	porB1b	1041	1041	96.18	porB1b.l15.c4.ctg.1	1497	176.3	0	.	p	.	0	N134E	NONSYN	400	402	AAT	709	711	GAG	230;232;234	G;A;G	214;215;217	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2652	porB1b	1041	1041	96.18	porB1b.l15.c4.ctg.1	1497	176.3	0	.	p	.	0	V135F	NONSYN	403	405	GTG	712	714	TTT	235;234;235	T;T;T	215;214;218	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2652	porB1b	1041	1041	96.18	porB1b.l15.c4.ctg.1	1497	176.3	0	.	p	.	0	G140K	NONSYN	418	420	GGA	727	729	AAA	226;227;231	A;A;A	214;213;217	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2652	porB1b	1041	1041	96.18	porB1b.l15.c4.ctg.1	1497	176.3	0	.	p	.	0	K143E	NONSYN	427	429	AAA	736	738	GAA	228;226;225	G;A;A	213;209;208	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2652	porB1b	1041	1041	96.18	porB1b.l15.c4.ctg.1	1497	176.3	0	.	p	.	0	V151A	NONSYN	451	453	GTA	760	762	GCA	224;221;221	G;C;A	210;207;204	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2652	porB1b	1041	1041	96.18	porB1b.l15.c4.ctg.1	1497	176.3	0	.	p	.	0	R187Q	NONSYN	559	561	CGA	868	870	CAA	199;202;202	C;A;A	187;191;189	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2652	porB1b	1041	1041	96.18	porB1b.l15.c4.ctg.1	1497	176.3	0	.	p	.	0	N189S	NONSYN	565	567	AAC	874	876	AGC	201;199;200	A;G;C	189;185;184	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2652	porB1b	1041	1041	96.18	porB1b.l15.c4.ctg.1	1497	176.3	0	.	p	.	0	T213L	NONSYN	637	639	ACA	946	948	TTA	202;202;203	T;T;A	190;191;191	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2652	porB1b	1041	1041	96.18	porB1b.l15.c4.ctg.1	1497	176.3	0	.	p	.	0	A244V	NONSYN	730	732	GCA	1039	1041	GTA	209;208;209	G;T,C;A	192;191,1;191	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2652	porB1b	1041	1041	96.18	porB1b.l15.c4.ctg.1	1497	176.3	0	.	p	.	0	G253Q	NONSYN	757	759	GGA	1066	1068	CAA	182;181;176	C;A;A	171;173;169	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2652	porB1b	1041	1041	96.18	porB1b.l15.c4.ctg.1	1497	176.3	0	.	p	.	0	.	INDELS	760	761	AC	1070	1073	ATCG	173;173;169;164	A;T;C;G	167;165;162;158	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2652	porB1b	1041	1041	96.18	porB1b.l15.c4.ctg.1	1497	176.3	0	.	p	.	0	.	INDELS	763	764	TG	1076	1079	TAGT	169;169;171;169	T;A;G;T	161;162;163;163	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2652	porB1b	1041	1041	96.18	porB1b.l15.c4.ctg.1	1497	176.3	0	.	p	.	0	A257D	NONSYN	769	771	GCT	1084	1086	GAT	173;172;171	G;A;T	162;164;164	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2652	porB1b	1041	1041	96.18	porB1b.l15.c4.ctg.1	1497	176.3	0	.	p	.	0	V270A	NONSYN	808	810	GTA	1123	1125	GCG	184;186;187	G;C;G	171;172;174	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2652	porB1b	1041	1041	96.18	porB1b.l15.c4.ctg.1	1497	176.3	0	.	p	.	0	D293S	NONSYN	877	879	GAT	1192	1194	AGT	235;236;237	A;G;T	212;210;208	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2652	porB1b	1041	1041	96.18	porB1b.l15.c4.ctg.1	1497	176.3	1	SNP	p	G120K	1	.	.	358	360	AAG	666	668	CGG	219;219;220	C;G;G	206;203;203	porB1b.WHO_M_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2652	porB1b	1041	1041	96.18	porB1b.l15.c4.ctg.1	1497	176.3	1	SNP	p	A121D	1	.	.	361	363	GAC	669	672	CGC	220;221;220	C;G;C	203;208;207	porB1b.WHO_M_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2652	porB1b	1041	1041	96.18	porB1b.l15.c4.ctg.1	1497	176.3	1	SNP	p	D121N	0	.	.	361	363	GAC	669	672	CGC	220;221;220	C;G;C	203;208;207	porB1b.WHO_M_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	10440	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4912	211.9	0	.	p	.	0	R364W	NONSYN	1090	1092	CGG	1385	1387	TGG	247;245;242	T;G;G	230;230;230	.	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	10440	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4912	211.9	1	SNP	p	H553N	0	.	.	1657	1659	CAT	1952	1954	CAT	208;208;203	C;A;T	189;187;183	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_F_02142c	rpsJ.WHO_F_02142c	1	1	27	1062	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	928	113.8	1	SNP	p	V57M	0	.	.	169	171	GTG	494	496	GTG	254;254;255	G;T;G	233;232;234	rpsJ.WHO_F_02142c:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
